Research
Hormonal
Tirzepatide (5, 10, 15 mg weekly) produces substantial, dose-dependent weight loss in patients with obesity or overweight with comorbidities, outperforming placebo.
Tirzepatide is a dual GIP/GLP-1 agonist that produces significant, dose-dependent weight loss (up to 17.8% at 15 mg weekly). It is administered subcutaneously once weekly. As of September 2023, it was not approved for obesity treatment in Switzerland, so availability may be limited.
StrongSupportsHIGH confidence
Nach 72-wöchiger Therapie konnte das Gewicht in der Tirzepatid-Gruppe placebokorrigiert um durchschnittlich 11,9 % (Dosis: 5 mg), 16,4 % (Dosis: 10 mg) bzw. 17,8 % (Dosis: 15 mg) reduziert werden.
Why this rating
Based on the SURMOUNT-1 Phase III trial cited.
Source
Neue Behandlungsmöglichkeiten der Adipositas
Ellen Heitlinger et al. · 2024
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →